|Bid||40.76 x 100|
|Ask||42.24 x 600|
|Day's Range||41.65 - 42.40|
|52 Week Range||29.39 - 47.82|
|PE Ratio (TTM)||32.10|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.90|
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. ...
The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
After two years on the sidelines, Morgan Stanley is taking a more bullish bet on Mylan NV (NASDAQ: MYL ). A Tuesday upgrade boosted Mylan's ratings ratio to 13 Buys and seven Holds. The Rating Analyst ...
Mylan (MYL) is on the move Tuesday, thanks to an upgrade from Morgan Stanley. Analyst David Risinger boosted his rating on the stock to Overweight from Equal Weight and raised his price target to $50 from $39. Risinger writes that he's bullish on Mylan because it has better growth prospects than its peers, thanks to its pipeline. Other analysts have also argued that Mylan is the only specialty pharma stock worth buying, and the stock got a boost after reporting upbeat earnings earlier this month.
Mylan N.V.'s stock ran up 3.8% in morning trade Tuesday, after Morgan Stanley analyst David Risinger turned bullish on the generic drug maker for the first time, citing greater confidence in growth prospects ...
Among the companies with shares expected to trade actively in Monday's session are Target, CVS Health, McDonald's, Netflix, United Parcel Service and 3M.
Stock Monitor: Eagle Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 06, 2018 / Active-Investors.com has just released a free research report on Mylan N.V. (NASDAQ: MYL ). If you want access ...
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Mylan N.V. said Friday it is planning to launch two new low-cost HIV combination treatments in the U.S. The company said Symfi Lo and Cimduo won U.S. Food and Drug Administration approval in February. ...